Common Contracts
8 similar Sales Agreement contracts by Inmune Bio, Inc., BioLineRx Ltd., KalVista Pharmaceuticals, Inc., others
At-the-market SALES AGREEMENTSales Agreement • June 14th, 2021 • OncoCyte Corp • In vitro & in vivo diagnostic substances • New York
OncoCyte Corporation, a California corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC in its capacity as sales agent for the Company (“BTIG” and, together with the Company, the “Parties”), as follows:
At-the-market SALES AGREEMENTSales Agreement • March 11th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
INmune Bio Inc., a Nevada corporation ( the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
MATINAS BIOPHARMA HOLDINGS, INC. UP TO $50,000,000 OF COMMON STOCK (par value $0.0001 per share) At-the-market SALES AGREEMENTSales Agreement • July 2nd, 2020 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
Matinas Biopharma Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
INMUNE BIO INC. UP TO $10,000,000 OF COMMON STOCK (par value $0.001 per share) At-the-market SALES AGREEMENTSales Agreement • April 17th, 2020 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
INmune Bio Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
BIOLINERX LTD. Up to $30,000,000 of American Depositary Shares, each representing one ordinary share (par value NIS 0.10 per share) AT-THE-MARKET SALES AGREEMENTSales Agreement • October 31st, 2017 • BioLineRx Ltd. • Pharmaceutical preparations • New York
BioLineRx Ltd., a corporation formed under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
KALVISTA PHARMACEUTICALS, INC. COMMON STOCK (par value $0.001 per share) AT- THE-MARKET SALES AGREEMENTSales Agreement • July 13th, 2017 • KalVista Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
PULMATRIX, INC. UP TO $11,000,000 OF COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENTSales Agreement • March 17th, 2017 • Pulmatrix, Inc. • Pharmaceutical preparations • New York
Pulmatrix, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
URANIUM RESOURCES, INC. UP TO $15,000,000 OF COMMON STOCK (par value $0.001 per share) AT-THE-MARKET SALES AGREEMENTSales Agreement • October 31st, 2011 • Uranium Resources Inc /De/ • Metal mining • New York
URANIUM RESOURCES, INC., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
